Medico Remedies Ltd
NSE:MEDICO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (43.3), the stock would be worth ₹68.27 (63% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 26.6 | ₹41.91 |
0%
|
| 3-Year Average | 43.3 | ₹68.27 |
+63%
|
| 5-Year Average | 43.3 | ₹68.27 |
+63%
|
| Industry Average | 25.6 | ₹40.33 |
-4%
|
| Country Average | 23.3 | ₹36.72 |
-12%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Medico Remedies Ltd
NSE:MEDICO
|
3.5B INR | 26.6 | 30 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 29.2 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 21.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.9 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.6 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 11.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 10.1 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 8.9 | 16.8 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 15.7 |
| Median | 23.3 |
| 70th Percentile | 34.7 |
| Max | 48 145.1 |
Other Multiples
Medico Remedies Ltd
Glance View
Medico Remedies Ltd. engages in the manufacture, supply, and exportation of pharmaceutical drugs. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2018-02-08. The firm is engaged in the manufacturing of medicines, including diuretics, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDS) tablets, antireterovirals, anti-ulcer drugs and antacids tablets. The company also manufactures and markets other drugs, such as anti-depressants, anti-epileptics, anti-psychotics capsules, antifungals, oral suspension, syrups, ointment creams and injectable. Its products include Isoniazid Tablets BP 300 milligram (mg), Aciclovir Tablets 400 mg, Metronidazole Vaginal Tablets 500 mg, Cotrimoxazole Tablets 960 mg, Mefenamic Acid Capsules 250mg, Celecoxib Capsules 200 mg, Piroxicam Capsules BP 40mg, Mefenamic Acid Tablets 250 mg, Enalapril Tablets BP 20mg, Phenytoin Sodium Capsules 100 mg, Clotrimazole Vaginal Inserts USP 100 mg, Artemether and Lumefantrine Tablets, Glibenclamide Tablets 5mg and Dolmed (Ibu) Cream.
